Evan Pisick, M.D.
- Bladder Cancer
- Genitourinary Cancers
- Kidney Cancer
- Melanoma
- Pancreatic Cancer
- Prostate Cancer
- Testicular Cancer
- Immunotherapy
- Targeted Therapies
- Thoracic Malignancies
- Gastrointestinal Malignancies
- Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research
- Referring Physicians Phone(847) 746-9990
- Referring Physicians Fax(847) 342-4089
- Referring Physicians Email[email protected]
Evan Pisick, M.D., is a medical oncologist at City of Hope® Cancer Center Chicago. Double board-certified in medical oncology and hematology, Dr. Pisick evaluates and treats a wide range of cancer types using innovative diagnostic and therapeutic techniques, such as tumor-infiltrating lymphocyte (TIL) therapy. In addition to being an experienced clinician, he is committed to educating and advocating for his patients so that they understand their disease and play an active role in determining their course of treatment.
Dr. Pisick earned his medical degree at Boston University, then completed both an internship and residency in internal medicine at Mount Sinai Medical Center in New York City. He then completed a fellowship in hematology at Tufts Medical Center in Boston.
A physician scholar with multiple publications to his name, Dr. Pisick has conducted extensive research on small cell and non-small lung cancer, as well as malignant mesothelioma. A member of the Association of Pathology Chairs Pathology Honor Society, he’s had his work published in peer-reviewed publications such as Hematology/Oncology Clinics of North America and the Journal of Experimental Therapeutics and Oncology.
Location
Chicago Cancer Center
Zion, IL 60099
Education & Experience
Board Certification
- Medical Oncology and Hematology — American Board of Internal Medicine
Degree
- Boston University School of Medicine, Boston, MA
Residency
- Internal Medicine — Mount Sinai Medical Center, New York, NY
Fellowship
- Hematology Oncology — Tufts Medical Center, Boston, MA
Publications
- Pisick E, Salgia R. Molecular biology of malignant mesothelioma: a review. Hematol Oncol Clin North Am. 2005 Dec;19(6):997-1023.
- Pisick E, Jagadeesh S, Salgia R. Receptor tyrosine kinases and inhibitors in lung cancer. ScientificWorldJournal. 2004 Aug 6;4:589-604.
- Pisick E, Jagadeesh S, Salgia R. Small cell lung cancer: from molecular biology to novel therapeutics. J Exp Ther Oncol. 2003 Nov-Dec;3(6):305-318.
- Pisick E, Skarin AT, Salgia R. Recent advances in the molecular biology, diagnosis and novel therapies for various small blue cell tumors. Anticancer Res. 2003 Jul-Aug;23(4):3379-3396.
- Salgia R, Harpole D, Herndon JE 2nd, Pisick E, Elias A, Skarin AT. Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. Anticancer Res. 2001 Mar- Apr;21(2B):1241-1246.
- Rubin BP, Skarin AT, Pisick E, Rizk M, Salgia R. Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer. Eur J Cancer Prev. 2001 Feb;10(1):77-82.
- Sattler M, Pisick E, Morrison PT, Salgia R. Role of the cytoskeletal protein paxillin in oncogenesis. Crit Rev Oncog. 2000;11(1):63-76.
- Salgia R, Li JL, Ewaniuk DS, Wang YB, Sattler M, Chen WC, Richards W, Pisick E, Shapiro GI, Rollins BJ, Chen LB, Griffin JD, Sugarbaker DJ. Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene. 1999 Jan 7;18(1):67-77.
- Salgia R, Li JL, Ewaniuk DS, Pear W, Pisick E, Burky SA, Ernst T, Sattler M, Chen LB, Griffin JD. BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest. 1997 Jul 1;100(1):46-57.
- Sattler M, Salgia R, Shrikhande G, Verma S, Pisick E, Prasad KV, Griffin JD. Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120(CBL). J Biol Chem. 1997 Apr 11;272(15):10248-10253.